

## [Isoprenaline](#)

Not recommended as an essential medicine

Section:

[12. Cardiovascular medicines 12.2. Antiarrhythmic medicines](#)

Codes ATC: [C01CA02](#)

Indication

Bradycardia Code ICD11: [MC81.1](#)

INN

Isoprenaline

Type de médicament

Chemical agent

Type de liste

Liste complémentaire

Formulations

**Parenteral > General injections > IV:** 20 µg per mL in ampoule (hydrochloride)

Historique des statuts LME

Ajouté pour la première fois en 1993 ([TRS 850](#))

Modifié en 1997 ([TRS 882](#))

Retiré en 2005 ([TRS 933](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Isoprenaline](#)

DrugBank

[Isoprenaline](#)

Résumé des preuves et recommandation du comité d'experts

During its meeting in 2003, the Committee recommended that isoprenaline be reviewed for possible fast-track deletion at the meeting in 2005. The Committee noted that there was no published evidence to support the efficacy of isoprenaline in the emergency treatment of bradycardia. This was supported by the ISDB review which also concluded that cardiac pacing and other drug therapies provide effective, safer alternatives. The Japan Institute of Pharmacovigilance proposed that isoprenaline be retained because it is needed in the treatment of transient and reversible severe bradycardia where cardiac pacing is unavailable, and in the treatment of beta-blocker overdose. Unfortunately, no data were submitted to support these assertions, and the Committee could not find good clinical studies to support its efficacy and safety. The Committee therefore recommended that isoprenaline be deleted from the Model List because of the lack of evidence and the very limited indications for its use.